The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,168.00
Ask: 12,172.00
Change: 108.00 (0.90%)
Spread: 4.00 (0.033%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Car industry: Better be selective

Wed, 08th Jul 2020 12:28

* European shares slip

* Wall Street rose overnight

* UK's Sunak to map out next moves in recovery plan
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

CAR INDUSTRY: BETTER BE SELECTIVE (1100 GMT)

The car industry is seen recovering in the second half of 2020 as lockdowns easing in Europe
continues, but will investors be willing to buy auto shares?

In terms of sales and production, barring a post-vacation second wave of infections in
Europe, the industry is expected to suffer from some seasonality impact in Q3 2020, before
picking up strongly in Q4.

But auto share prices could drop further in UBS' worst-case scenario, which includes a 17%
drop in global sales in 2020, as "cascading effects" might step in, such as recapitalisation
needs.

In the Swiss bank's base scenario, with a 9% drop in global sales and production, the STOXX
auto index tracked the drop in earnings, which the bank "sharply" reduced.

UBS suggests being selective and "buy names with a strong balance sheet and cash generation,
an above-average degree of cost flexibility" and which can be winners in the transition to
electric cars, such as Volkswagen, Hella, Michelin.

(Stefano Rebaudo)

*****

GOODBYE MR BOND (0950)

Much has been written on how the 60/40 equity/bond portfolio split -- beloved of fund
managers of a certain vintage -- is losing its mojo.

The blame falls squarely on the G7 government bond, which provides neither income in good
times or safety when things go sour.

Some reckon a investment-grade corporate bonds are in a position to assume the safe-haven
role once played by government debt, given they are now backstopped by central bank purchases.
But a recent JPMorgan note advised ditching the 60/40 altogether in favour of other number
combos.

One suggestion they make is to cut down on bond allocations and go 80/20. Another is a
20/40/40 mix of bonds, hybrids and equities. (As the name suggests, hybrids are a cross between
stocks and bonds and include things like preferred shares or convertible debt)

Or forget bonds altogether and go for a 60/40 hybrid/equity portfolio. (Returns would be a
respectable 5% a year, JPM estimates).

Finally, what about 80/20 but with the bond component comprised half-and-half of junk and
top-grade debt.

As for returns on all these options, they range 4%-5% a year. That doesn't sound like much
more than the 3.5% JPM expects from the traditional 60/40, but as it points out: it adds up over
the years.

(Sujata Rao)

*****

SUNAK'S TIME TO IMPRESS (0909 GMT)

All eyes will be on UK's Sunak, who will unveil later today (around 1130 GMT) his plans to
revamp the economy as he tries to prevent the UK to fall into an unemployment crisis.

What shall we expect in terms of stocks reaction?

The quick answer is not much, as there has been a fair amount of reports anticipating some
of his planned moves, analysts suggest.

But fresh stimulus can always "have a positive impact" on the FTSE, says Ipek Ozkardeskaya,
senior analyst at Swissquote Bank.

Here're a few details on Sunak's plans:

- a 2 billion-pound fund to create six-month work-placement jobs for unemployed 16-24
year-olds.

- 3 billion pounds to improve the energy efficiency of homes and public buildings.

- he is reportedly considering a stamp duty holiday and giving away vouchers to boost
spending in hospitality businesses.

Some analysts' comments:

Deutsche Bank - "Our UK economists’ base case is that Sunak will broadly stick to the
mandate set out by PM Johnson last week, possibly topping up the package by another 0.2% of GDP,
focusing particularly on apprenticeship schemes, and modest wage subsidies to get furloughed
employees back into work".

UniCredit - "We certainly do not expect the government to extend the jobs retention scheme;
indeed, while the government accepts the likelihood of a big increase in job losses when the
scheme ends, it appears to have made a judgement that many of these jobs would ultimately be
lost anyway, and that it's better to support a reallocation of these workers to growth sectors".

LCG Research - "High hopes for more infrastructure spending, business grants or tax cuts
could quickly disappear if the focus remains on keeping jobs".

(Joice Alves)

*****

OPENING SNAPSHOT: WAIT AND SEE MOOD (0740 GMT)

European stocks are in negative territory as a surge in coronavirus cases in the U.S. has
clouded hopes for a swift economic recovery.

Investors are in a wait and see mood ahead of the upcoming earnings season, and next week's
ECB meeting and EU summit where leaders will discuss the recovery fund.

Britain's finance minister will announce later today his next moves to prevent a wave of job
cuts from snowballing into an unemployment crisis.

The STOXX 600 index is down 0.3% with banks leading losses down 1.2%, while oil and
gas shares drop 0.5% as oil prices dipped on renewed oversupply fears after data showed a build
in U.S. crude stockpiles.

Shares in Electrolux are among the best performers of the STOXX 600, up 6%, after
the company reported a smaller than expected loss. Victrex stocks, touched a
three-month lows, and are now down almost 4% after the company's trading update.

(Stefano Rebaudo)

*****

ON THE RADAR: INSURERS, BOOHOO, ASTRAZENECA, MERCK (0650 GMT)

European stocks are set for a session in the red, with investors in wait and see mode ahead
of the upcoming earnings session, while they are trying to assess if rising cases in the U.S.
will lead to more restrictive measures.

On the corporate front, commercial insurers are facing hefty claims from the coronavirus
crisis but are also seeing a steep rise in premiums – tempting companies and industry veterans
to raise capital, launch new businesses or expand into new lines. Lloyd's of London, insurers
Beazley, Hiscox and Lancashire are among those to raise equity.

AstraZeneca and Merck & Co said their blockbuster cancer treatment Lynparza
won approval in the European Union for treating patients with a form of pancreatic cancer.

Zalando will delist all products made by Britain's Boohoo following a
media report about dire working conditions in a English factory that supplied the popular brand.
Boohoo decided to launch an independent review of its supply chain in Britain.

Shares in Traton down 3.6% after the company announced management change.
Deutsche Post stocks up 1.3% in early trade after reporting a 16% rise
in second-quarter operating profit.

FirstGroup warned on its ability to continue as a going concern, after posting an
annual operating loss as passenger volumes plummeted due to the coronavirus crisis.

Electrolux said it will report a smaller loss for the second quarter of 2020 than
previously anticipated, with operating income estimated at about 100 million crown.

OMV Q2 output dropped 5% in wake of coronavirus pandemic.

Other headlines:

Diaceutics says sales for first half increased by 20%

Britain's Funding Circle to cut 85 U.S. jobs

Marlowe plc says FY adjusted profit before tax up 54%

Liontrust Asset Management says net inflows of £971 mln in 3 months ended 30 June 2020

Amigo Holdings appoints Glen Crawford as CEO

Italy's Stefanel draws 4 expressions of interest, expects more

(Stefano Rebaudo)

*****

MORNING CALL: NOT MUCH TO LOOK FORWARD TOO (0545 GMT)

European bourses seem poised to open in negative territory this morning with little to look
forward to after Asia and Wall Street failed to gain momentum and switched to 'wait-and-see'.

Futures for pan-European blue chips, the DAX and the FTSE were down 0.7%, 0.6% and 0.8%
respectively.

The resurgent coronavirus pandemic is keeping Wall Street in check while in Asia, the
bullishness surrounding Chinese shares failed to spread significantly across beyond the region.

Very little macro indicators or corporate events in Europe today to help markets find their
way.

Looking forward, investors will be eager to get into the Q2 earnings season to see for
themselves if the V-shaped recovery priced in the market is indeed on its way.

(Julien Ponthus)

*****

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.